Efficacy and Safety of SJP-0132 in Patients With Dry Eye Disease: A Phase 2b Randomized, Double-Masked, Dose-Finding Study
SJP-0132 showed generally dose-dependent efficacy and safety. Based on safety and treatment benefits with SJP-0132 0.3% in the overall population and in subgroups, this dose was considered optimal for further development.
Authors
- Yuichi Hori (ORCID: https://orcid.org/0000-0002-3781-7976)
- Kohei Omatsu (ORCID: https://orcid.org/0000-0003-4897-5029)
- T Wada (ORCID: https://orcid.org/0000-0001-8753-1506)
Institutions
- Toho University (JP)
- Senju Pharmaceutical (Japan) (JP)
Publication Details
- Journal
- American Journal of Ophthalmology
- Published
- 2025-12-04
- DOI
- https://doi.org/10.1016/j.ajo.2025.11.036
- Citations
- 1
- Primary Topic
- Ocular Surface and Contact Lens
- Type
- article
- Field-Weighted Citation Impact
- 1.88